Reference : Risque de restenose et d'evenements cardiaques apres angioplastie coronaire chez le p...
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
Human health sciences : Cardiovascular & respiratory systems
Risque de restenose et d'evenements cardiaques apres angioplastie coronaire chez le patient diabetique: reduction par des approches pharmacologiques systemiques.
[en] Incidence of restenosis and cardiac events after coronary angioplasty in diabetic patients: reduction by systemic pharmacological approaches
Legrand, Victor mailto [Centre Hospitalier Universitaire de Liège - CHU > > Cardiologie >]
Scheen, André mailto [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Nyssen, Astrid [ > > ]
Revue Médicale de Liège
Hopital de Baviere
Yes (verified by ORBi)
[en] Angioplasty, Transluminal, Percutaneous Coronary/adverse effects ; Anti-Inflammatory Agents/therapeutic use ; Antioxidants/therapeutic use ; Belgium/epidemiology ; Cardiovascular Agents/therapeutic use ; Coronary Restenosis/epidemiology/prevention & control ; Coronary Thrombosis/therapy ; Diabetes Complications/prevention & control ; Diabetes Mellitus, Type 2/complications ; Drug Therapy, Combination ; Evidence-Based Medicine ; Fatty Acids, Omega-3/therapeutic use ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Hypoglycemic Agents/therapeutic use ; Immunologic Factors/therapeutic use ; Incidence ; Meta-Analysis as Topic ; Platelet Aggregation Inhibitors/therapeutic use ; Randomized Controlled Trials as Topic ; Stents
[en] Various systemic pharmacological approaches have been evaluated to reduce the risk of restenosis after coronary angioplasty, with or without stent, in the general population and in diabetic patients who are at increased risk for such complication. The aim of the present paper is to describe the effects of the main pharmacological classes on the risk of restenosis, the need for new revascularisation procedures and the incidence of major clinical events (MACE: death, myocardial infarction, revascularisation). We will analyse the role of antiplatelet agents, omega-3 fatty acids, statins, anti-inflammatory compounds, immunomodulators, anti-oxidants, glitazones and, finally, classical antidiabetic drugs such as metformin and insulin. Whenever possible, we will focus our attention on the results obtained in the diabetic population.
Researchers ; Professionals ; Students

File(s) associated to this reference

Fulltext file(s):

Open access
200904_05.pdfPublisher postprint383.75 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.